BioSpace News Archive

Visitors to Demo Widex ENERGY CELL™ Technology and Get a Live Hearing Demo of Second Generation Widex EVOKE™

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced the appointment of Natalie Holles, president and chief operating officer of Audentes Therapeutics, as a member of the company’s board of directors and Greg Whitehead as senior vice president and chief quality officer

Micronic released the new innovative 2.00ml Tubes with External thread. These 2.00ml tubes are the first tubes of its kind, enabling researchers to store high volume samples in a space-efficient 96-well format

New working capital intended to advance Ehave’s development of digital assessments and therapeutic games for children with ADD/ADHD, ASD, and other mental health disorders.

Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, shared results yesterday from its open label study, ALK4290-201.

Inovio Pharmaceuticals, Inc. announced the appointment of Dr. Ann C. Miller to its Board of Directors.

Centene Corporation announced that following the release of its 2019 first quarter financial results on Tuesday, April 23, 2019, the Company will hold its 2019 Annual Meeting of Stockholders at 11:00 a.m. (Eastern Time)/10:00 a.m. (Central Time) in the auditorium at Centene’s headquarters, 7700 Forsyth Boulevard, St. Louis, Missouri.

Findings show that performing multiple immunization protocols in parallel can yield greater antibody diversity

Health Care Service Corporation, the nation’s largest customer-owned health insurer, has named Monica Diaz as vice president and chief diversity & inclusion officer, reporting to Nazneen Razi, senior vice president and chief human resources officer, HCSC.

Bone Biologics Corp. has announced that it received Human Research Ethics Committee approval on March 20, 2019, for the first center of a multicenter pilot clinical trial to evaluate NB1 in 30 patients in Australia.